ClinicalTrials.gg
Not yet recruitingNCT07554872Updated Nov 19, 2026

Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease

A Phase 1 interventional study of Neural Stem Cell-Derived Exosomes in Alzheimer Disease (AD), sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shanghai Mental Health Center · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Planned enrollment
170th of 176
9 · median 100
Started
2027
the only one that year
Phase 1
26 of 260
18 open now
Primary completion
2027-10
later than 95 of 161 live
Registered
224th of 260
by date
Lead sponsor
8 of 260
Shanghai Mental Health Center

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 170th largest by planned enrollment of the 176 interventional ones that give a count, is the only one that started in 2027, is one of 26 in phase 1, reaches primary completion later than 95 of the 161 other live ones, and was the 224th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease. The study aims to evaluate the safety, tolerability, and preliminary efficacy of neural stem cell-derived exosomes (NSC-EVs) administered by the intranasal route. A total of 9 participants will be enrolled in 3 frequency-escalation groups: once every 3 days, once every other day, and once daily, each for 28 days. Participants will undergo screening and baseline assessment, a 28-day treatment period, and follow-up visits at 4, 8, and 24 weeks after the end of treatment.

Read the detailed description

Early-onset moderate-to-severe Alzheimer's disease imposes a substantial burden on patients and families, and there is currently no truly effective treatment capable of reversing the pathological process. Neural stem cell-derived exosomes (NSC-EVs) are considered a promising therapeutic approach because they may have low immunogenicity, the ability to cross the blood-brain barrier, and a more standardized manufacturing pathway than cell-based therapy.

This study is designed as an open-label, single-center, three-group phase I clinical study to explore the safety, tolerability, and preliminary efficacy of intranasal NSC-EVs in patients with moderate-to-severe early-onset Alzheimer's disease. The study uses a 3+3 frequency-escalation design with sentinel-participant monitoring to determine the highest tolerated dosing frequency and to generate preliminary clinical data for future larger-scale studies.

A total of 9 participants are planned for enrollment. Participants will be assigned sequentially to 1 of 3 dosing-frequency groups: low-frequency, medium-frequency, or high-frequency. All groups will receive the same investigational product by intranasal administration for 28 days, with differences only in dosing frequency. The low-frequency group will receive treatment on Days 1, 4, 7, 10, 13, 16, 19, 22, 25, and 28; the medium-frequency group will receive treatment on Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27; and the high-frequency group will receive treatment daily from Day 1 through Day 28.

After the 4-week treatment period, participants will enter a follow-up phase with visits scheduled at 4 weeks, 8 weeks, and 24 weeks after the end of treatment. Assessments during treatment and follow-up will include safety monitoring, clinical laboratory testing, cognitive and neuropsychiatric evaluations, and protocol-defined biomarker and imaging assessments as applicable. The primary objective is to evaluate safety and tolerability, while secondary and exploratory objectives include preliminary evaluation of cognitive, behavioral, functional, and biomarker changes over time.

03

Conditions studied

  • Alzheimer Disease (AD)

Browse trials for

Keywords

  • Early-Onset Alzheimer's Disease
  • Moderate-to-Severe Alzheimer's Disease
  • Neural Stem Cell-Derived Exosomes
  • Intranasal Administration
  • Phase I Clinical Study
  • Frequency Escalation
  • Safety
  • Tolerability
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 50 to 75 years.
  • Meets the 2011 NIA-AA criteria for probable Alzheimer's disease dementia.
  • Age at onset ≤65 years.
  • CMMS score 5-20
  • Stable dose for at least 2 months before enrollment if receiving pro-cognitive or psychiatric medications.
  • Primary school education or above and able to complete study-required cognitive assessments.
  • Hachinski Ischemic Score ≤4.
  • GDS-30 total score ≤10.
  • Screening brain MRI+DWI+SWI meeting protocol-defined cerebrovascular exclusion thresholds and no major structural abnormalities inconsistent with Alzheimer's disease.
  • Positive amyloid pathology confirmed by Aβ-PET at screening or before enrollment.
  • Adequate vision and hearing to complete assessments.
  • Has a reliable caregiver able to accompany the participant to study visits and provide information for assessments.
  • Willing to participate and sign .

Exclusion criteria

Exclusion Criteria:

  • Dementia due to causes other than Alzheimer's disease.
  • Brain MRI showing any of the following: Fazekas white matter hyperintensity score >2; more than 2 lacunar infarcts >1.5 cm; lacunar infarcts involving critical regions such as the thalamus, hippocampus, entorhinal cortex, or parahippocampal region; cerebral hemorrhage, subdural hematoma, aneurysm, arteriovenous malformation, intracranial mass lesion, or other structural abnormalities.
  • Allergy to stem cell-derived exosomes or PET examination.
  • Severe psychiatric disorder or symptoms.
  • Significant active physical illness, including severe cardiac disease, severe systemic infection, or severe liver/kidney dysfunction.
  • Elevated tumor markers or tumor history.
  • Immune-related disease.
  • Significant nasal obstruction.
  • Serious suicide risk.
  • Participation in another clinical trial or stem cell therapy within the past 6 months.
  • Any other condition judged inappropriate by the investigator.
  • to MRI or inability to complete MRI examinations, including non-MRI-compatible metallic implants, certain stents, plates, pacemakers, or severe claustrophobia.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Low-Frequency NSC-EVs

    Participants receive neural stem cell-derived exosomes by intranasal administration once every 3 days for 28 days. The single dose is 6 × 10\^9 particles administered into both nostrils. In the low-frequency group, dosing is scheduled on Days 1, 4, 7, 10, 13, 16, 19, 22, 25, and 28, for a total of 10 doses.

    Biological: Neural Stem Cell-Derived Exosomes

  • Experimental
    Medium-Frequency NSC-EVs

    Participants receive neural stem cell-derived exosomes by intranasal administration every other day for 28 days. The single dose is 6 × 10\^9 particles administered into both nostrils. In the medium-frequency group, dosing is scheduled on Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27, for a total of 14 doses.

    Biological: Neural Stem Cell-Derived Exosomes

  • Experimental
    High-Frequency NSC-EVs

    Participants receive neural stem cell-derived exosomes by intranasal administration once daily for 28 days. The single dose is 6 × 10\^9 particles administered into both nostrils. In the high-frequency group, dosing is scheduled daily from Day 1 through Day 28, for a total of 28 doses.

    Biological: Neural Stem Cell-Derived Exosomes

Interventions

  • BiologicalNeural Stem Cell-Derived Exosomes

    The investigational product is a neural stem cell-derived exosome preparation administered intranasally. The product specification is 6 × 10\^9 particles per 2 mL vial. The product is thawed to room temperature before administration and delivered into both nostrils. The same investigational product is used in all study groups; the groups differ only in dosing frequency.

    Also known as: NSC-EVs

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Related Adverse Events

    Number of participants experiencing treatment-related adverse events assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

    Time frame: Baseline to Week 4

  2. Number of Participants With Treatment-Related Clinical Laboratory Abnormalities

    Number of participants with treatment-related clinical laboratory abnormalities during the treatment period.

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Change in Chinese Mini-Mental Status (CMMS) Score

    Cognitive function will be assessed using the Chinese Mini-Mental Status (CMMS), a Chinese-language screening instrument for global cognitive impairment. Total scores range from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

  2. Change in Severe Impairment Battery (SIB) Score

    Cognitive function will be assessed using the Severe Impairment Battery (SIB), a validated instrument for cognitive function in moderate-to-severe dementia. Total scores range from 0 to 100, with higher scores indicating better cognitive performance.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

  3. Change in Neuropsychiatric Inventory (NPI) Score

    Neuropsychiatric symptoms will be assessed using the Neuropsychiatric Inventory (NPI), a standardized instrument for behavioral and psychological symptoms in dementia. Total scores range from 0 to 144, with higher scores indicating greater neuropsychiatric symptom burden.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

  4. Change in Geriatric Depression Scale (GDS) Score

    Depressive symptoms will be assessed using the 30-item Geriatric Depression Scale (GDS-30), a questionnaire designed to assess depressive symptoms in older adults. Total scores range from 0 to 30, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

  5. Change in Pittsburgh Sleep Quality Index (PSQI) Score

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a questionnaire that evaluates subjective sleep quality and sleep disturbance. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

  6. Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score

    Functional ability will be assessed using the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), a caregiver-based instrument used to evaluate daily functioning in patients with Alzheimer's disease. Total scores range from 0 to 78, with higher scores indicating better functional ability.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

  7. Change in Zarit Burden Interview (ZBI) Score

    Caregiver burden will be assessed using the Zarit Burden Interview (ZBI), a questionnaire used to evaluate the perceived burden experienced by caregivers. Total scores range from 0 to 88, with higher scores indicating greater caregiver burden.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

  8. Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score

    Global dementia severity will be assessed using the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), which evaluates impairment across multiple cognitive and functional domains. Total scores range from 0 to 18, with higher scores indicating greater dementia severity.

    Time frame: Baseline, Week 4 (end of treatment), and 4, 8, and 24 weeks after end of treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2027, 9 months later.

Of 73 non-industry phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 9 months is below that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jan 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartEst.
Jan 2027was May 2026
Primary completionEst.
Oct 20, 2027
CompletionEst.
Dec 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 2026→Jan 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date May 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07554872
Collaborators
Shanghai Angecon Biotechnology Co., Ltd.
Responsible party
Ling YUE (Principal Investigator, Shanghai Mental Health Center) — Principal investigator
First posted
Apr 28, 2026
Start date
Jan 2027 (estimated)
Primary completion
Oct 20, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Yue Ling 岳玲, MD, PhD
Contact
bellinthemoon@hotmail.com
18017311249

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion